News
Galectin Therapeutics Completes Enrollment of Second Cohort of Phase 1 Trial of GR-MD-02 for NASH (Fatty Liver Disease) With Advanced Fibrosis
April 23, 2014 | Press ReleaseGalectin Therapeutics Announces First Patient Dosed in Second Cohort of Phase 1 Trial of GR-MD-02 for NASH With Advanced Fibrosis
April 17, 2014 | Press ReleaseFirst Cohort Results in Galectin Therapeutics’ Phase 1 Trial Reveal Biomarker Evidence of Therapeutic Effect on Fibrosis and Inflammation in NASH With Advanced Fibrosis
March 31, 2014 | Press ReleaseGalectin Therapeutics to Announce Results From First Cohort of Phase 1 Clinical Trial in Fatty Liver Disease
March 25, 2014 | Press ReleaseHighlights
View Galectin Therapeutics’ webcast discussing first cohort results of Phase 1 clinical trial of GR-MD-02 in NASH
April 1, 2014 | WebcastView a webcast featuring Galectin Therapeutics’ CEO presenting at 16th Annual BIO CEO & Investor Conference
February 10, 2014 | WebcastView the most recent Galectin Therapeutics Corporate Presentation
February 10, 2014 | ResourceGalectin Therapeutics Reports on Key 2013 Scientific, Development and Regulatory Milestones, Highlights Corporate and Financial Activity
January 8, 2014 | Press ReleaseGalectin Therapeutics CEO Discusses Fatty Liver Disease as the “Silent Epidemic” on Nationally Syndicated Radio Show
July 8, 2013 | Radio Interview
Galectin Therapeutics, Inc.
NASDAQ: GALT
12.00-0.32 Stock price update every 30 minutes.